1. 87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM. (April 2015) Authors: Ades, L.; Guerci-Bresler, A.; Makhoul, P. Cony; Legros, L.; Delaunay, J.; Recher, C.; Sebert, M.; Lejeune, J.; Chevret, S.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 91 IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE. (April 2015) Authors: Brechemier, D.; Comont, T.; Bertoli, S.; Dutertre, M.; Recher, C.; Adoue, D.; Beyne-Rauzy, O. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 94 IMPACT OF COMORBIDITIES ON OVERALL SURVIVAL IN THE ELDERLY WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA TREATED BY AZACITIDINE. Issue 1 (April 2015) Authors: Brechemier, D.; Bertoli, S.; Comont, T.; Balardy, L.; Recher, C.; Lauwers-Cances, V.; Beyne-Rauzy, O. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. Issue 1 (January 2016) Authors: Bulai Livideanu, C.; Apoil, P. A.; Lepage, B.; Eischen, M.; Laurent, C.; Laharrague, P.; Lamant, L.; Tournier, E.; Tavitian, S.; Pouplard, C.; Recher, C.; Laroche, M.; Mailhol, C.; Dubreuil, P.; Hermine, O.; Blancher, A.; Paul, C. Journal: Clinical & experimental allergy Issue: Volume 46:Issue 1(2016:Jan.) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). (September 2016) Authors: Dupont, H.; Marolleau, J.P.; Totet, A.; Damiani, C.; Berceanu, A.; Larosa, F.; Bonhomme, J.; Chabrot, C.; Bouteille, B.; Boutoille, D.; Gastinne, T.; Peterlin, P.; Gari Toussaint, M.; Poisson, D.; Briet, D.; Buret, J.; Legrand, M.; Denis, B.; Raffoux, E.; Bergeron, A. Journal: Clinical microbiology and infection Issue: Volume 22:Number 9(2016) Page Start: 810.e1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE. (23rd June 2022) Authors: de Botton, S.; Choe, S.; Marchione, D.; Montesinos, P.; Recher, C.; Vives Polo, S.; Zarzycka, E.; Wang, J.; Bertani, G.; Heuser, M.; Calado, R.; Schuh, A.; Yeh, S.-P.; Hui, J.; Pandya, S.; Gianolio, D.; Daigle, S.; DiNardo, C.; Dohner, H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P477: PHENOTYPICALLY-DEFINED STAGES OF LEUKEMIA ARREST PREDICT MAIN DRIVER MUTATIONS SUBGROUPS, AND OUTCOME IN ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Vergez, F.; Largeaud, L.; Bertoli, S.; Nicolau-Travers, M.-L.; Rieu, J.-B.; Vergnolle, I.; Saland, E.; Sarry, A.; Tavitian, S.; Huguet, F.; Picard, M.; Vial, J.-P.; Lechevalier, N.; Bidet, A.; Dumas, P.-Y.; Pigneux, A.; Luquet, I.; Mansat-De Mas, V.; Delabesse, E.; Carroll, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P510: THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: DiNardo, C.; Pratz, K.; Panayiotidis, P.; Wei, X.; Vorobyev, V.; Illés, Á.; Kim, I.; Ivanov, V.; Ku, G.; Miller, C. L.; Zhang, M.; Tatsch, F.; Potluri, J.; Schmidt, X.; Recher, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML. (23rd June 2022) Authors: Daver, N. G.; Montesinos, P.; Aribi, A.; Martinelli, G.; Altman, J.; Roboz, G.; Wang, E. S.; Burke, P. W.; Jeyakumar, D.; Walter, R. B.; DeAngelo, D. J.; Erba, H. P.; Advani, A.; Gastaud, L.; Thomas, X.; Todisco, E.; Pemmaraju, N.; Mendez, L.; de la Fuente, A.; Gaidano, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 454 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE. (23rd June 2022) Authors: Schuh, A.; de Botton, S.; Recher, C.; Vives Polo, S.; Zarzycka, E.; Wang, J.; Bertani, G.; Heuser, M.; Calado, R.; Yeh, S.-P.; Hui, J.; Pandya, S.; Gianolio, D.; Chamberlain, C.; Dohner, H.; Montesinos, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗